Next-Gen BVA Device Promises Faster, More Accurate Fluid Management for Millions of Patients
Daxor Corporation (DXR), a global leader in blood volume measurement, has received FDA 510(k) clearance for its new rapid, compact, handheld Blood Volume Analyzer (BVA), marking a significant advancement in patient-specific fluid management. Designed for both hospital and outpatient settings, this lab-based device quantifies blood volume with high precision, addressing a longstanding gap in clinical care.
“For decades, clinicians have relied on imprecise or invasive methods to estimate blood volume,” said Michael Feldschuh, Daxor’s President and CEO. “Our new device revolutionizes care by providing fast, accurate data wherever a lab is available.”
Blood volume derangement contributes to a wide array of conditions—heart failure, sepsis, trauma, dialysis, and surgery—costing billions annually. With 7+ million heart failure patients and over 7 million critical care admissions each year, accurate volume measurement is essential.
Using the gold standard tracer dilution technique, BVA™ offers laboratory-grade accuracy in just one-third the time of its predecessor. Weighing only 7 pounds, it enables rapid deployment in resource-limited settings and delivers critical data to avoid both hypovolemia and hypervolemia complications.
Dr. John L. Jefferies, Daxor’s Chief Medical Officer, highlighted its clinical impact: “BVA-guided care has shown up to 86% reduction in heart failure mortality and 56% fewer readmissions in peer-reviewed studies.”
Developed with the U.S. Department of Defense, the device is backed by research from Duke, the Mayo Clinic, and the Cleveland Clinic. With over 75,000 tests shipped and five decades of research, Daxor is setting a new standard in precision diagnostics—empowering clinicians across cardiology, nephrology, emergency care, and beyond to deliver better, data-driven outcomes.
You might like this article:Tariffs Dull E.l.f. Beauty’s Shine Despite Beating Expectations
